A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer’s Disease and Mild Cognitive Impairment

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease

(2017) Nour K. Majbour et al.   Scientific Reports

CSF α-Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease

(2017) Fransje E. Reesink et al.   JOURNAL OF ALZHEIMERS DISEASE

Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study

(2016) Guro Berge et al.   BMC Neurology

Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders

(2016) Xuling Li et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients

(2016) Shashank Shekhar et al.   PLoS One

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

(2015) Ju-Hee Kang et al.   Alzheimers & Dementia

Neuronal response in Alzheimer’s and Parkinson’s disease: the effect of toxic proteins on intracellular pathways

(2015) Shohreh Majd et al.   BMC NEUROSCIENCE

Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization

(2015) Filsy Samuel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study

(2015) Wai-Ying Wendy Yau et al.   LANCET NEUROLOGY

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

(2015) Tessandra Stewart et al.   Acta Neuropathologica Communications

Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease

(2014) Marta Swirski et al.   Alzheimers Research & Therapy

Phosphorylation Modulates Clearance of Alpha-Synuclein Inclusions in a Yeast Model of Parkinson's Disease

(2014) Sandra Tenreiro et al.   PLoS Genetics

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid- 1-42 and   Proteins as Alzheimer Disease Biomarkers

(2013) J.-H. Kang et al.   CLINICAL CHEMISTRY

Classification and Epidemiology of MCI

(2013) Rosebud Roberts et al.   CLINICS IN GERIATRIC MEDICINE

Neuropathologic substrates of Parkinson disease dementia

(2012) David J. Irwin et al.   ANNALS OF NEUROLOGY

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

(2012) Sara Hall et al.   ARCHIVES OF NEUROLOGY

Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

(2012) Paul K. Crane et al.   Brain Imaging and Behavior

A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment

(2012) Laura E. Gibbons et al.   Brain Imaging and Behavior

Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains

(2012) Douglas G. Walker et al.   EXPERIMENTAL NEUROLOGY

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

(2012) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Phosphorylated  -Synuclein in Parkinson's Disease

(2012) Y. Wang et al.   Science Translational Medicine

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

(2011) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

(2011) Brit Mollenhauer et al.   LANCET NEUROLOGY

Interaction between -Synuclein and Other Proteins in Neurodegenerative Disorders

(2011) Kurt A. Jellinger   TheScientificWorldJOURNAL

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

(2010) Zhen Hong et al.   BRAIN

A Pathologic Cascade Leading to Synaptic Dysfunction in  -Synuclein-Induced Neurodegeneration

(2010) D. A. Scott et al.   JOURNAL OF NEUROSCIENCE

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Early Diagnosis of Alzheimers Disease: Is MCI Too Late?

(2009) Ronald Petersen   Current Alzheimer Research

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease

(2008) Kurt A. Jellinger et al.   ACTA NEUROPATHOLOGICA

Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases

(2008) Igor F. Tsigelny et al.   PLoS One

Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies

(2007) Kimiko Obi et al.   EXPERIMENTAL NEUROLOGY